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[D-AlaZ,(2R,3S)- VPhe4,Leu5]enkephalin (CP-OH) [ Vdenoting cyclopropyl; superscript E indicating the E-configuration 
about the cyclopropane ring], a highly selective opioid ligand for 6 receptors in rat brain, but not for those in the mouse 
vas deferens, was examined for in vivo biological activities by intracerebroventricular administration. CP-OH (5-20 pg) 
showed no analgesic activity in the hot plate (51°C) test using rats. However, it suppressed completely the analgesic effects 
of intraperitoneally administered morphine (3 mg/kg rat) in a dose-dependent manner. CP-OH showed no binding affini- 
ty for brain K receptors to which dynorphin, an opioid peptide that inhibits morphine analgesia, binds predominantly. 
These results suggest that, besides the conventional 6 receptors which mediate analgesia, the rat brain contains another 
d-like receptor which has a modulatory role to attenuate morphine-induced analgesia mediated through the p receptors, 
and that this modulatory receptor does not exist in the mouse vas deferens. 
Opiate receptor; Analgesia; Antagonism; Enkephalin analog; Receptor heterogeneity 
1. INTRODUCTION 
The synthetic opioid peptide, [D-Ala2,(2R, 
3S)- V EPhe4,Leu5]enkephalin (CP-OH), contains 
a conformationally restricted amino acid E-(2R, 
3S)-cyclopropylphenylalanine ( V EPhe) (fig. 1) [ 11. 
We have recently reported that CP-OH can dis- 
crimate between the 6 opiate receptors in rat brain 
and in the mouse vas deferens (MVD), interacting 
with the former, but not with the latter [2]. Thus, 
it was suggested that the 6 receptors in rat brain are 
different from those in the MVD. 
[D-Pen2,D-Pen’lenkephalin (DPDPE) and [D- 
Ala2,D-Leu’lenkephalin (DADLE) are very potent 
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and selective for the 6 receptors in rat brain [3]. 
They are also active in the peripheral tissue of the 
MVD. There is a distinct difference between the 
biological profiles of these peptides and of CP- 
OH, since CP-OH has no agonist or antagonist ac- 
tivities in the MVD in spite of its high affinity for 
rat brain 6 receptors [2]. These results inevitably 
raised a fundamental question, i.e. what is the ac- 
tivity of CP-OH in rat brain? In the present study, 
we have examined the possible thermal analgesic 
activity of CP-OH by intracerebroventricular 
(i.c.v.) administration. We also examined the abili- 
ty of CP-OH to potentiate morphine-induced 
analgesia, since such an effect has been described 
for DADLE [4,5]. Herein we report the results of 
these in vivo biological assays for VEPhe4-en- 
kephalin, and discuss a possible new role of brain 
6 receptors in the multiple opiate receptor system. 
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Fig. 1. Chemical structure of [D-AlaZ,(2R,3S)- V EPhe4,Leu5]- 
enkephalin. 
2. MATERIALS AND METHODS 
2.1. Drugs 
CP-OH was synthesized by the solution method, the synthesis 
having been described in [I]. [D-Ala2,MePhe4,Gly- 
o15]enkephalin (DAGO), DADLE and bremazocine were pur- 
chased from Sigma (St. Louis, MO). DPDPE was purchased 
from Bachem (Bubendorf, Switzerland). Morphine sulfate was 
obtained from Takeda (Osaka). 
2.2. In viva biological assays 
Chronic cannulas (A 0.8, L 1.4, V 3.3, Bregma) were im- 
planted in the cerebral ventricle of a separated group of male 
Wistar rats (220-270 g) anesthetized with intraperitoneally in- 
jected sodium pentobarbital (40 mg/kg rat). These rats were 
housed for a week to recover from surgery. Drugs were ad- 
ministered i.c.v. (5 aI) and rats were tested at 15 min postdrug 
administration. Each rat was placed on the hot plate 
(51 T O.S”C) and the time (s) required to lick the rear paw was 
recorded. 
In order to examine the effect of the peptide CP-OH on 
morphine-induced analgesia, morphine (3 mg/kg rat) was first 
injected i.p. and the peptide was administered i.c.v. (5 ~1) after 
15 min. Rats were then tested at 15 min postdrug administra- 
tion on the hot plate to record the latency (s) to lick the rear 
paw. 
2.3. Receptor-binding assay 
Receptor-binding assays using rat brain membrane prepara- 
tions were carried out essentially as in [6]. (-)- 
[9-3H(n)JBremazocine (41.4 Ci/mmol, New England Nuclear) 
was used as a tracer specific for the x receptors. Incubations 
were carried out for 90 min at 25°C in 50 mM Tris-HCI buffer 
(pH 7.4) containing DADLE (100 nM) and DAGO (100 nM) as 
masking ligands of the 6 and p receptors, respectively, and also 
bacitracin (100 /g/ml) as an enzyme inhibitor. 
3. RESULTS AND DISCUSSION 
It has been reported that DADLE and DPDPE 
produce significant analgesia in the hot plate test 
after i.c.v. administration in rats [7]. Since 
DPDPE is a highly d-selective ligand in the central 
nervous system (CNS) and produces analgesia, it 
was suggested that both 6 and y receptors in brain 
mediate analgesia [7]. CP-OH is also highly selec- 
tive for 6 receptors in the CNS. In the binding 
assays using rat brain homogenate and the tracer 
[3H]DADLE or [3H]DPDPE, CP-OH and 
DPDPE showed very similar dose-response curves 
and exhibited similar potencies [2]. However, in 
the present study, CP-OH showed no analgesic ef- 
fects at all in the hot plate test using rats. The i.c.v. 
administration of CP-OH (5, 10, 20 pg) produced 
no increases in hot plate (51°C) latencies (s) (fig.2) 
indicating that the peptide lacks anti-nociceptive 
activity. This striking result indicates that equally 
potent ligands in the binding assay showed com- 
pletely different in vivo effects on analgesia, i.e. 
DPDPE was active, whereas CP-OH was inactive. 
Vaught and Takemori [4] and Barrett and 
Vaught [5] reported that Leu’-enkephalin, 
DADLE, and [D-Ser2,Leu5]enkephalyl-Thr6, puta- 
tive S-selective ligands, administered i.c.v. at 
subanalgesic doses potentiated morphine-induced 
analgesia in the tail-flick assay using mice and, 
thus, it was suggested that the 6 receptors play an 
indirect modulatory role in analgesia. Here, we 
also examined the effect of CP-OH on morphine- 
induced analgesia, by injecting CP-OH (0, 10, 
20 yg i.c.v.) into rats after administration of mor- 
phine (3 mg/kg i.p.). Surprisingly, CP-OH an- 
tagonized the thermal analgesic activity of 
morphine very effectively in a dose-dependent 
manner (fig.3). This suppressive ffect of CP-OH 
on morphine analgesia is in sharp contrast with the 
reported morphine potentiation described for 
other S-selective ligands. Since it is difficult to ac- 
cept the idea that these opposite in vivo effects are 
mediated through the same opiate receptors, we 
performed further investigations. 
Friedman et al. [S] reported that dynorphin- 
(l-13), itself devoid of analgesic activity, 
significantly suppressed analgesia induced by mor- 
phine in the mouse tail-flick test. Since dynorphin 
is known to interact with x receptors in the brain 
[9], we suspected that CP-OH might be attenuating 
morphine analgesia by interacting with the x recep- 
tors. Thus, we examined the binding ability of CP- 
OH for K receptors in rat brain using 
[3H]bremazocine as a x tracer. Due to considerable 
binding of bremazocine to 6 and p receptors, in- 
cubations were carried out in the presence of 
DADLE (100 nM) and DAGO (100 nM) to mask 
6 and p receptors, respectively. As shown in fig.4, 
unlabeled bremazocine displayed a concentration- 
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Fig.2. Analgesic effect of i.c.v. administered VEPhe4- 
enkephalin in the hot-plate (51°C) assay at 15 min postdrug in- 
jection. Bars represent means + SE of responses of 4-5 rats per 
dose. 
dependent displacement curve with 1% = 1.13 
nM, while DADLE and DAGO showed very weak 
affinity with I&I values of > 10 and 2.4,~M, 
respectively. Clearly, CP-OH and DPDPE ex- 
hibited no binding at all in this assay (fig.4). These 
results indicate that the suppression of morphine- 
induced analgesia by CP-OH is not mediated 
through the x receptors. 
These results clearly show that CP-OH, namely 
[D-Ala2,(2R,3S)- VEPhe4,Leu4]enkephalin, 
belongs to a new class of highly receptor-selective 
opioid ligands. In the CNS, CP-OH exhibited a 
high affinity for 6 receptors, but not for p and x 
receptors and, moreover, suppressed morphine- 
induced analgesia. In the peripheral tissues, CP- 
OH exhibited no agonist or antagonist activities. 
Although there are limitations to the use of data 
obtained from an in vivo procedure for differentia- 
tion of receptor functions, these results strongly 
suggest that the brain 6 receptors play a negative 
modulatory role in p receptor-mediated morphine 
analgesia. 
At this point, however, there is still a fundamen- 
tal and unresolved discrepancy between the in vivo 
activities of CP-OH and DPDPE, both of which 
are equally S-selective in the brain. One possible 
explanation is that the analgesic effect of DPDPE 
is not through the S receptors in the brain, but 
through those in the spinal cord, as suggested by 
Ohlsson et al. [lo] when they found that significant 
saline 1i.p.) / saline 5 v1 (i.c.v.1 
I nolphine (3 q/kg, i.p.1 / saline 5 ~1 6.c.v.) 
nomine (3 ny/kg, i.p.1 / v%k4-mk tug/S ~1. i.c.v.) 
Fig.3. Effect of VEPhe4-enkephalin on morphine-induced 
analgesia in the hot plate (51’C) test at 15 min postdrug injec- 
tion. Morphine (3 mg/kg rat) was injected i.p. and after 15 min 
the peptide dissolved in saline (5 ,ul) was administered i.c.v. For 
control experiments (CT), saline was injected i.p. instead of 
morphine. Bars represent means f SE of responses of 7-9 rats 
per dose. * Significantly different from control (* PcO.05, 
** P<O.Ol). 
fractions of i.c.v. injected peptides can reach the 
spinal cord. Indeed, DPDPE was reported to be a 
potent agonist for hot-plate analgesia t the spinal 
cord level [l 11. In this case, higher doses of CP- 
OH, which we could not achieve because of its 
solubility, might produce similar thermal analgesia 
by interacting with the spinal 6 receptors. Alter- 
natively, or more likely, the brain may have 
another ‘&like’ receptor to which CP-OH binds 
predominantly. In this receptor model, S-like 
receptors play a modulatory role in morphine- 
induced analgesia and the ‘conventional’ 6 recep- 
tors only mediate analgesia. CP-OH, then, in- 
teracts with the d-like receptors, but not with the 6 
receptors, while DPDPE and DADLE bind to 
both. 
Relating to the latter hypothesis, several 
biological and analytical studies suggesting an 
allosteric interaction between 6 and p receptors 
have been reported recently. Met5-enkephalin per 
se has an analgesic activity by i.c.v. administra- 
tion. However, it was found that this peptide also 
exhibits inhibitory activity against morphine- 
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Fig.4. Dose-response curves of opioid peptides and opiate in the 
radioligand receptor-binding assay using rat brain and [3H]- 
hremazocine. 
induced analgesia when a subanalgesic dose is in- 
jected i.c.v. [ 12,131. Since Met’-enkephalin at- 
tenuates whereas Let?-enkephalin potentiates 
morphine analgesia [4,5], Vaught et al. [13] 
postulated an allosteric coupling model between 
morphine @) and enkephalin (6) receptors, sug- 
gesting a modulatory role of 6 receptors in p- 
receptor-mediated analgesia. Furthermore, Roth- 
man and Westfall [14,15] analyzed this allosteric 
model by detailed receptor-binding studies and 
formulated the hypothesis that morphine and 
enkephalin allosterically modulate each other. In 
this one-site allosteric model, 6 receptor functions 
to mediate both agonist and antagonist messages. 
However, as mentioned above, it is unlikely that 
the opposite messages were transmitted through 
the same opiate receptors; Rothman et al. [16,17] 
then postulated a two-site allosteric model, based 
on the finding of the two distinct sites of 6 recep- 
tors. They showed that [3H]DADLE apparently 
labels two binding sites [ 161 and the binding to one 
site, a low-affinity [3H]DADLE-binding site, is in- 
hibited noncompetitively by the p-agonist oxymor- 
phone, suggesting an allosteric coupling between 
this site and ,B receptors [17]. Taking these results 
into consideration, it is most likely that our B-like 
receptor is the one coupled with p receptors in a 
two-site allosteric model by Rothman et al. [16,17] 
and CP-OH should be a highly selective and 
292 
specific ligand for this site. We tentatively 
designate this d-like receptor as the S-l receptor 
and the conventional S receptor as the 6-2 receptor, 
which may correspond to the type I and II S recep- 
tors, respectively, described by Rothman et al. 
[16]. Apparently, rat brain contains both 6-l and 
6-2 receptors, while mouse vas deferens contains 
only 6-2 receptor. 
In conclusion, by utilizing a highly specific 
enkephalin analog having conformational con- 
straints, the present study strongly suggests the ex- 
istence of a receptor which modulates p-mediated 
morphine analgesia. CP-OH will become a very 
useful peptide compound in studies aimed at clari- 
fying the molecular mechanism and functional role 
of this receptor in a complicated and multiple 
opiate ligand-receptor system. Further biological 
and pharmacological studies are in progress in our 
laboratory. 
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